Pharmacological inhibition of prolyl hydroxylase protects against inflammation‐induced anemia via efficient erythropoiesis and hepcidin downregulation

@article{Jain2019PharmacologicalIO,
  title={Pharmacological inhibition of prolyl hydroxylase protects against inflammation‐induced anemia via efficient erythropoiesis and hepcidin downregulation},
  author={Mukul Jain and A. Joharapurkar and V. Patel and S. Kshirsagar and B. Sutariya and Maulik D. Patel and Hiren Patel and P. Patel},
  journal={European Journal of Pharmacology},
  year={2019},
  volume={843},
  pages={113–120}
}
  • Mukul Jain, A. Joharapurkar, +5 authors P. Patel
  • Published 2019
  • Chemistry, Medicine
  • European Journal of Pharmacology
  • ABSTRACT Chronic inflammatory diseases are often associated with anemia. In such conditions, anemia is generally treated with erythropoiesis stimulating agents (ESAs) which are associated with potentially hazardous side effects and poor outcomes. Suboptimal erythropoiesis in chronic inflammation is believed to be caused by elevated hepcidin levels, which causes blockade of iron in tissue stores. In the current work using rodent models of inflammation, an orally available small molecule prolyl… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 44 REFERENCES
    Hepcidin‐dependent and hepcidin‐independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation
    25
    Hepcidin regulation in the anemia of inflammation
    55
    Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly.
    36
    Iron regulation and erythropoiesis
    171
    Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis.
    177
    The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.
    1430
    Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.
    239